Medical Associate Director, Nanomedicine CSL Vifor Ann Arbor
Nanomedicines represent a large and heterogenous class of drugs, many of which have inherently complex pharmacokinetic profiles that make computational modeling challenging. Challenges in measuring serum drug concentrations, evaluating unique distribution properties, and lack of traditional phase I or II metabolism pathways contribute to the complexity of model development.
The topics covered will be evidence-based examples of nanomedicine products which demonstrate challenges in determination of specific pharmacokinetic parameters (i.e. absorption, distribution, metabolism (biodegradation). Examples: Distribution of liposomal doxorubicin, physicochemical parameters of LNP vaccines and biodegradation of iron-carbohydrate nanoparticles.
Learning Objectives:
To identify and apply specific challenges in resolving pharmacokinetic parameters to develop physiologically based pharmacokinetic modeling for nanomedicines